What is Human Cell?
Human Cell Corporation operates at the intersection of advanced biotechnology and large-scale manufacturing, providing critical components for the research and development sector. The company specializes in the production of long-acting and xeno-free cytokines derived from HEK293 cells, a core requirement for modern human cell manufacturing processes. By offering low-endotoxin recombinant proteins, the firm serves as a vital partner for pharmaceutical entities and research institutions conducting complex animal model studies. Their market position is defined by a commitment to high-quality, scalable biological reagents that facilitate scientific innovation and streamline the transition from laboratory research to industrial-scale production.
How much funding has Human Cell raised?
Human Cell has raised a total of $30K across 1 funding round:
Debt
$30K
Debt (2021): $30K with participation from PPP
Key Investors in Human Cell
PPP
Public-Private Partnership
What's next for Human Cell?
Following this substantial expansion capital, Human Cell Corporation is expected to prioritize the optimization of its manufacturing capabilities and the broadening of its product portfolio. As the company navigates its current growth phase, strategic focus will likely shift toward increasing production capacity to meet the rising demand for high-purity reagents in the global biotech market. By leveraging its expertise in HEK293-derived cytokines, the firm is poised to capture additional market share, potentially exploring new partnerships within the pharmaceutical sector to further integrate its solutions into clinical-grade manufacturing workflows. The infusion of capital provides the necessary runway to enhance operational efficiencies and solidify its standing as a key supplier in the life sciences supply chain.
See full Human Cell company page
